T1	Participants 46 95	high-risk patients undergoing open heart surgery.
T2	Participants 277 363	open-label T3 was administered to 68 high-risk patients undergoing open heart surgery.
T3	Participants 1144 1213	patients with high estimated mortality undergoing open heart surgery.
